End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
56.1 CNY | +1.80% | +5.04% | -9.56% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 73.82 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.56% | 1.04B | - | ||
-15.40% | 18.83B | A | ||
-40.81% | 2.92B | C+ | ||
+19.34% | 1.9B | - | ||
+2.22% | 1.71B | - | ||
+26.55% | 1.26B | B+ | ||
-16.29% | 961M | - | C- | |
+0.59% | 779M | - | ||
-22.49% | 649M | B+ | ||
+12.26% | 520M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688212 Stock
- Ratings Shanghai AoHua Photoelectricity Endoscope Co., Ltd.